Clinical Trials Browser

Phase 2 × Chemotherapy-Related Cognitive Impairment × Mesna × Clear all

NCT01205503 2016-02-24

Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release

Phase 2 Completed

32 enrolled 24 charts

Chemotherapy-Related Cognitive Impairment, Breast Neoplasms, Lymphoma, Non-Hodgkin